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Background: This study evaluated the dose-response and dosing interval of the novel long-
acting muscarinic receptor antagonist (LAMA) GSK573719 in patients with COPD.
Methods: This randomized, double-blind, placebo-controlled, 3-way cross-over, incomplete
block study evaluated 5 once-daily doses of GSK573719 (62.5e1000 mg), 3 twice-daily doses
(62.5e250 mg), and open-label tiotropium for 14 days in patients (N Z 176) with COPD (FEV1
of 35e70% predicted). The primary endpoint was morning trough FEV1 at Day 15. Secondary
endpoints included 0e24 h weighted mean FEV1 and serial FEV1 values over 28 h. Safety
measures and pharmacokinetics were assessed.
Results: All once-daily doses of GSK573719 significantly increased trough FEV1 at Day 15 with
improvements ranging from 95 to 186 mL over placebo (p  0.006), from 79 to 172 mL with
twice-daily dosing (p  0.03), and 105 mL with tiotropium (pZ 0.003). No clear dose ordering
was observed. Once-daily doses significantly (p < 0.001) increased 0e24 h weighted mean FEV1
at Day 14 by 131e143 mL over placebo, comparable to increases with the twice-daily doses
(120e142 mL) and tiotropium (127 mL). Significant reductions in rescue albuterol use and
improvements in FVC were also observed with once-daily dosing. Plasma Cmax occurred within
5e15 min of dosing after which the drug was rapidly cleared and eliminated. GSK573719 was
well tolerated, with no apparent treatment-related changes in vital signs, ECG and Holter
assessments, or clinical laboratory parameters.and Critical Care Medicine, Institution: University of North Carolina, 4125 Bioinformatics Building,
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Effect of the novel LAMA GSK573719 in COPD patients 971Conclusion: Once-daily dosing with GSK573719 in COPD provides clinically significant and sus-
tained improvement in lung function over 24 h with similar efficacy to twice-daily dosing.
ª 2012 Elsevier Ltd. All rights reserved.Introduction capacity (FVC) ratio of 0.70 and a post-albuterol FEV1 ofVagal cholinergic tone is a major reversible mechanism
contributing to airway narrowing in chronic obstructive
pulmonary disease (COPD) with the release of acetylcholine
to airway smooth muscle. Acetylcholine acts through post-
synaptic muscarinic receptors to mediate airway smooth
contraction and mucus secretion.1 The bronchodilator
efficacy of inhaled anticholinergic agents in COPD is related
to the blocking of muscarinic receptors on airway smooth
muscle to prevent muscle contraction.2 The use of the
muscarinic antagonist ipratropium is limited for the main-
tenance treatment of COPD by a short duration of action
and a recommended dose that is suboptimal for maximal
bronchodilation.3 Long-acting anticholinergic bronchodila-
tors such as tiotropium have been developed to allow less
frequent dosing and improved efficacy over ipratropium
while providing acceptable side-effect profiles.4,5 Pres-
ently, additional long-acting anti-muscarinic agents are
being developed with potentially unique efficacy and safety
profiles and delivery via novel inhalers.6,7 Inhaled bron-
chodilators, including long-acting anticholinergics and b2-
receptor agonists, are fundamental to the pharmacologic
management of COPD and current disease management
guidelines recommend the use of long-acting bronchodila-
tors across a wide range of disease severities ranging from
moderate to very severe COPD.8e10
GSK573719 is a quinuclidine derivative that is a potent,
competitive inhaled muscarinic receptor antagonist in
development for the once-daily treatment of COPD, for use
as a monotherapy and in combination with the long-acting
b2-agonist vilanterol. Previous clinical pharmacology
studies have demonstrated that single and repeat dose
administration of GSK573719 is safe and well tolerated in
healthy volunteers and subjects with COPD with systemic
exposure limited by a low oral bioavailability.11,12 Similar to
tiotropium, the extended residence time of GSK573719 at
airway smooth muscle muscarinic receptors leads to sus-
tained bronchodilation.13
The primary objective of this study was to evaluate the
dose-response, safety and efficacy of 5 once-daily doses of
GSK573719 (62.5, 125, 250, 500, and 1000 mg), and the
efficacy and safety of 3 twice-daily doses of GSK573719
(62.5, 125, and 250 mg) and tiotropium 18 mg once-daily
compared with placebo in subjects with COPD. A secondary
objective was to evaluate the pharmacokinetic profile of
GSK573719 with repeat dosing in COPD.
Methods
Patients
Males and females aged 40e80 years with a history of COPD
and 10 pack years smoking history were enrolled.
At screening eligible patients had a post-albuterol (salbu-
tamol) forced expiratory volume in 1 s (FEV1)/forced vital35 and 70% of predicted normal. Patients with a current
diagnosis of asthma, a1-antitrypsin deficiency, any clini-
cally significant uncontrolled disease, a significant elec-
trocardiogram (ECG) or clinical laboratory finding, or
a lower respiratory tract infection or recent COPD exacer-
bation were excluded. Concurrent use of systemic corti-
costeroids, long-acting bronchodilators, including
theophyllines, and inhaled ipratropium was not allowed.
Patients could not have used oral or parenteral cortico-
steroids for 6 weeks, tiotropium for 14 days, and inhaled
long-acting b2-agonist for 48 h prior to screening. Concur-
rent use of inhaled corticosteroids at a stable dose was
allowed; patients using a fixed-dose combination of an
inhaled corticosteroid and long-acting b2-agonist were
allowed to switch to inhaled corticosteroid monotherapy at
an equivalent dose. Study participants were required to
provided written informed consent prior to study partici-
pation and the study was approved by local ethics review
committees and conducted in accordance with the Decla-
ration of Helsinki and Good Clinical Practice guidelines.Procedures
This was a multicenter, randomized, double-blind, double-
dummy, placebo-controlled, 3-way cross-over, incomplete
block study (GlaxoSmithKline study number AC4113073;
www.clinicaltrials.gov registration number NCT00950807)
conducted at 20 outpatient centers in the United States and
Germany. GSK573719 doses of 62.5, 125, 250, 500, and
1000 mg once-daily and 62.5, 125, and 250 mg twice daily,
administered using a multi-dose dry powder inhaler, were
evaluated over a 14-day treatment period. Investigators
and study participants were blinded to GSK573719 dose and
dose frequency by use of identical inhaler devices. Open-
label tiotropium inhalation powder (Spriva Handihaler;
Boehringer Ingelheim, Ingelheim, Germany) 18 mg once-
daily was included as a positive control. Patients were
provided with supplemental albuterol to use as required to
relieve breakthrough symptoms. Study withdrawal criteria
were a COPD exacerbation, a clinically significant labora-
tory finding, and various ECG or Holter findings defined as
clinically significant.
Eligible patients were randomized to a sequence of 3
treatments consisting of placebo and 2 of the 9 active
treatments. The treatment phase comprised 3 14-day
periods, each separated by a 10- to 14-day washout. A
follow-up phone contact for adverse assessment was con-
ducted approximately 1 week after the last study visit
(Fig. 1). Serial spirometry was obtained over 28 h at the end
of each treatment period at pre-dose, 1, 3, 6, 9, 12, 13, 15,
18, 21, 24, and 28 h after AM dosing, and the PM dose was
administered after the 12 h spirometry. At Day 1 of each
treatment period, 6 h serial spirometry was obtained pre-
dose and 1, 3, and 6 h after AM dosing. Pre-dose spirom-
etry was also obtained at Day 7. Serial plasma and urine
Figure 1 Study design. Patients received placebo and 2 of the 9 active treatments.
972 J.F. Donohue et al.samples were obtained to determine standard plasma and
urine pharmacokinetic parameters following which the
pharmacokinetic/pharmacodynamic relationship between
individual change from baseline in pulse rate and
GSK573719 Cmax was visually assessed.
The primary efficacy endpoint was the change from
baseline in clinic visit trough (pre-bronchodilator and 24 h
post-dose) FEV1 at the end of each treatment period (Day
15). Baseline was defined as the pre-dose FEV1 value
obtained at Day 1.
Secondary efficacy endpoints were 0e24 h weighted
mean FEV1 at Day 14 and serial FEV1 values at each time
point over 28 h at Day 14. Additional endpoints included
weighted mean FEV1 over 0e6 h, peak FEV1, FVC assess-
ments, and rescue albuterol use.
Safety evaluations included adverse events, vital signs,
12-lead ECG and 24 h Holter assessments (obtained at
screening and at the end of each treatment period),
standard clinical laboratory tests, and COPD exacerba-
tions. Patients recorded any medical problems on diary
cards. The entries were reviewed at each study visit and
study investigators were responsible for detecting, doc-
umenting, and reporting adverse events. Study investiga-
tors were not instructed to specifically inquire about
adverse events commonly associated with inhaled anti-
cholinergics such as dry mouth. An exacerbation was
defined as an acute worsening of symptoms of COPD
requiring the use of any treatment beyond study medica-
tion or rescue albuterol.
Statistical analysis
The planned sample size was 117 evaluable subjects. The
study was designed to provide adequate power for the
comparisons of active treatments (once- and twice-daily
GSK573719 doses and tiotropium) with placebo. The sample
size calculations assumed 90% power, a 2-sided 5% signifi-
cance level, a within-subject standard deviation of 159 mL
and a treatment difference from placebo of 130 mL. The
primary analysis was performed on the Modified Intent-to-
Treat (MITT) population, consisting of all subjects who were
randomized and received study medication, analyzed
according to actual treatment received, and used a mixed
model including baseline FEV1, mean baseline FEV1, treat-
ment and period as fixed effects and subject as a random
effect.Multiplicity across the comparisons of each once-daily
GSK573719 dose with placebo was controlled by using
a step-down closed testing procedure whereby a statistical
comparison of the highest dose with placebo was initially
performed and subsequent comparisons at lower doses
continued in a step-down manner only if the preceding
comparison was significant at the 5% level. Other compar-
isons of active treatments with placebo were considered
exploratory and were not adjusted for multiplicity.
Weighted mean and peak FEV1 and FVC endpoints and
the mean number of puffs per day of rescue albuterol were
analyzed similarly to the primary endpoint. Serial FEV1 and
FVC were analyzed using a mixed model including baseline,
mean baseline, treatment, period, time, time by baseline
interaction, time by mean baseline interaction and time
by treatment interaction as fixed effects and subject as
a random effect.
Vital signs (pulse rate, systolic and diastolic blood
pressure) and ECG parameters (QTc(F) and QTc(B)) were
analyzed at each post-treatment time point at which they
were recorded, using a mixed model including baseline,
mean baseline, treatment and period as fixed effects and
subject as a random effect.
Phamacokinetic parameters AUC0t, Cmax, tmax and tlast
were determined using non-compartmental methods from
the plasma concentration-time data for each day for each
subject. Dose proportionality PK analyses were performed
if sufficient data were available. To evaluate the accumu-
lation ratio Ro, statistical analyses of AUC0t and Cmax were
performed after log transforming the data.
Results
Study population
A total of 324 patients were screened to randomize 176
patients who received at least 1 dose of study treatment;
135 (77%) completed all treatment periods (Fig. 2). Three
additional patients were randomized in error and did not
receive any study treatment. Between 3% and 11% of
patients were withdrawn while receiving each active
treatment, compared with 4% whilst receiving placebo.
Reasons for withdrawal during treatment were meeting
study stopping criteria (7%), withdrawal of consent (5%),
adverse event (3%), COPD exacerbation (3%), protocol
deviation (<1%), and lost to follow-up (<1%). Baseline
Figure 2 Patient disposition.
Effect of the novel LAMA GSK573719 in COPD patients 973demographic and clinical characteristics are shown in Table
1. Patients were predominantly Caucasian and had
moderate-to-severe disease with post-albuterol FEV1 values
ranging from 35 to 72% of predicted normal. Concurrent use
of inhaled corticosteroids ranged from 21 to 39% of patientsTable 1 Baseline characteristics.
MITT populationa
(n Z 176)
Age, yearsb 59.7 (8.12)
Male/female, n (%) 101/75 (57/43)
Race, n (%)
Caucasian 172 (98)
African American 4 (2)
Body mass index (kg/m2)b 26.71 (4.655)
FEV1 (L)
b,c 1.65 (0.467)
FEV1 % of predicted normal
b,c 52.4 (9.47)
FEV1 responsiveness to albuterol (%) 17.0 (14.81)
FEV1/FVC %
b,c 49.6 (9.77)
Smoking history in pack-yearsb 52.2 (27.48)
FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital
capacity.
a MITT Z modified intent-to-treat.
b Values are mean (SD).
c 10e30 min after albuterol (360 mg) administration.across the treatments, and the majority (70%) of patients
were current smokers.
Efficacy
All once-daily doses of GSK573719 significantly increased
trough FEV1 at 24 h on Day 15 compared with placebo with
adjusted mean differences of 128, 147, 95, 140 and 186 mL
for 62.5, 125, 250, 500, and 1000 mg once-daily, respec-
tively (p  0.006). These findings were similar to differ-
ences observed with twice-daily dosing (79, 134, and
172 mL for 62.5 mg, 125 mg, and 250 mg twice daily,
respectively; p  0.030) and tiotropium (105 mL,
p Z 0.003). Similar results were obtained at Day 7, with
trough FEV1 values ranging from 80 to 149 mL with once-
daily dosing, 100e151 mL with twice-daily dosing and
108 mL with tiotropium (p  0.006). Improvements in
airflow obstruction were sustained over 28 h, with all once-
daily doses of GSK573719 showing significant (p  0.033)
improvements in FEV1 values at all timepoints over 28 h
compared with placebo, with the exception of the 500 and
1000 mg once-daily doses at 1 h. The adjusted mean change
from baseline in serial FEV1 over 28 h with once- and twice-
daily dosing and tiotropium is shown in Fig. 3a and b,
respectively. Improvements in serial FEV1 over 28 h were
similar with once- and twice-daily dosing, and administra-
tion of a second dose of GSK573719 at 12 h following the
Figure 3 Adjusted mean change from baseline in FEV1 (L) over 28 h on Day 14 with (a) GSK573719 once daily (qd) and (b)
GSK573719 twice daily (bid).
974 J.F. Donohue et al.morning dose did not result in a marked improvement in
FEV1 for any of the twice-daily doses tested (Fig. 3b).
Statistically significant (p < 0.001) increases in the
adjusted mean change from baseline in 0e24 h, 0e12 h, and
12e24 h weightedmean FEV1 on Day 14 were observed for all
GSK573719 once- and twice-daily doses and tiotropium
comparedwith placebo,with no clear difference in effect for
all doses of GSK573719 tested (Fig. 4, Table 2). With once-
daily dosing, treatment differences from placebo in 0e24 h
weighted mean FEV1 ranging from 131 to 143 mL were
comparable to improvements with twice-daily dosing
(120e142 mL) and tiotropium (127 mL). On Day 1, change
frombaseline to peak FEV1 valueswithGSK573719 once-daily
ranged from262 to289mL, andchange frombaseline in 0e6hweighted mean values ranged from 160 to 199 mL with once-
daily dosing (Table 2). Similar resultswere obtained at Day 14
and with twice-daily dosing (Table 2).
Improvement in lung function with GSK573719 was
further confirmed by significant increases in trough FVC and
0e6 h and 0e24 h weighted mean FVC at all doses of
GSK573719 (Table 2). Similar to the FEV1 findings, a clear
dose-response was not observed for the effects on
GSK573719 on FVC measures.
At baseline, the mean daily use of rescue albuterol
ranged from 3.21 to 4.83 puffs/day. Significant reductions
in rescue albuterol use compared with placebo were
observed for all GSK573719 doses except the 62.5 mg and
1000 mg once-daily doses (Table 2).
Figure 4 Adjusted mean differences from placebo in change from baseline for 0e24 h weighted mean FEV1 (L) at Day 14. Error
bars are 95% confidence intervals. qd Z once daily; bid Z twice daily.
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The incidence of on-treatment adverse events was similar
with GSK573719 at doses of 62.5 mg and 125 mg given either
once-daily or twice-daily and tiotropium (17%e23%)
comparedwith placebo (16%), with an increased incidence at
higher doses of GSK573719 (30%e41%, Table 3). Headache
and cough were generally the most commonly reported
adverse events across treatments. Adverse events reported
by 5% ormore of patients in any treatment group are shown in
Table 3. A total of 3 serious adverse events were reported, 2
during treatment with GSK573719 250 mg once-daily (COPD
exacerbation and concussion) and 1 during treatment with
125 mg twice-daily (COPD exacerbation). None of these
events were fatal or considered related to study treatment
by the reporting investigator. The incidence of adverse
events leading towithdrawalwas 3%with placebo and ranged
from 0% to 8% across the GSK573719 doses with no apparent
treatment-related effect. The incidence of on-treatment
COPD exacerbations was low and similar across the treat-
ment groups (0%e3% with GSK573719 and 2% with placebo).
There were no apparent treatment-related changes in
vital signs, ECG and Holter assessments, and clinical labo-
ratory parameters. The overall incidence of patients with
one or more abnormal, clinically significant, post-
treatment ECG with GSK573719 treatment ranged from 5%
to 21%, comparable with incidence with placebo (13%). No
clear patterns in the rates of single ventricular ectopic
beats, couplets or runs were seen across treatments. Single
ectopics occurred in 81% of placebo-treated patients
compared with 60e84% of subjects across all GSK573719
doses. Couplets occurred in 14% of placebo-treated
subjects and 3e24% of patients across the GSK573719
doses. The incidence of ventricular runs was low (2% with
placebo and 0%e3% with GSK573719).
Pharmacokinetics
At all dose levels of GSK573719, the plasma concentration
profile indicated that Cmax occurred early at a median tmaxof 5e15 min following which the drug was rapidly cleared
and eliminated. Geometric mean Cmax data indicated that
by Day 7 steady-state had been achieved and there was
very little increase in GSK573719 systemic exposure from
Day 7 to Day 14. Urine pharmacokinetic data for GSK573719
at steady-state showed that approximately 2.5e3.0% of the
total dose administered was excreted unchanged in urine
(Fe) within the first 12 h for all twice-daily doses, and
approximately 2.0e3.1% of the total dose administered was
excreted unchanged in urine (Fe) 24 h post-dose for all
once-daily doses. There was no obvious association
observed between the individual change from baseline in
pulse rate on Day 14 and GSK573719 Cmax, suggesting that
plasma concentrations at steady-state at the highest dose
in this study did not affect pulse rate (Fig. 5).Discussion
The results of this study demonstrate that the novel long-
acting anticholinergic GSK573719 at doses ranging from
62.5 to 1000 mg once-daily significantly improved pulmonary
function as assessed by post bronchodilator FEV1 and FVC
for up to 28 h compared with placebo in patients with
moderate to severe COPD. There was no evidence for
tachyphylaxis over the 14-day treatment period and the
magnitude of effect on pulmonary function was comparable
with tiotropium.
Change from baseline in clinic visit trough FEV1 on Day
15 was selected as the primary efficacy endpoint as it
provides an accepted measure of bronchodilation to eval-
uate duration of action and to make inferences on bron-
chodilator activity at the end of the once- and twice-daily
dosing intervals. All once-daily doses of GSK573719 signifi-
cantly increased (p  0.006) trough FEV1 by 95e186 mL over
placebo. These improvements were comparable with
twice-daily dosing (79e172 mL), indicating that twice-daily
dosing of GSK573719 did not provide additional benefit over
once-daily dosing, particularly for comparisons of the same
total daily dose given once- or twice-daily or when a lower
total daily dose given twice-daily was compared with
Table 2 Adjusted mean change from baseline in trough, peak and weighted mean FEV1 and FVC (mL) and albuterol use (p fs/day).
GSK573719 once-daily GSK573719 wice-daily
Placebo 62.5 mg 125 mg 250 mg 500 mg 1000 mg 62.5 mg 125 mg 250 mg Tiotropium
n Z 158 n Z 35 n Z 34 n Z 36 n Z 38 n Z 32 n Z 34 n Z 37 n Z 33 n Z 35
FEV1 (mL)
Trough (Day 15) 47(17) 81 (33)** 99 (34)** 48 (33)* 92 (32)** 138 (36)** 32 (35) 87 (34)** 124 (34)** 58 (33)*
Peak Day 1 103 (12) 265 (24)** 258 (24)** 283 (24) ** 289 (23)** 262 (25)** 183 (24) 251 (23)** 216 (25)** 215 (24)**
Peak Day 14 105 (17) 313 (35)** 245 (35)** 296 (34)** 219 (33)** 215 (37)* 249 (36) 257 (35)** 257 (36)** 346 (35)**
0e6 h weighted
mean Day 1
29 (11) 178 (21)** 172 (22)** 199 (21)** 195 (21)** 160 (22)** 104 (22) 154 (21)** 133 (22)** 130 (21)**
0e6 h weighted
mean Day 14
2 (14) 167 (29)** 154 (29)** 176 (28)** 113 (28)** 108 (30)** 129 (30) 128 (29)** 146 (30)** 189 (29)**
0e24 h weighted
mean Day 14
59(14) 85 (25)** 77 (25)** 77 (25)** 72 (24)** 80 (27)** 62 (26) 83 (25)** 75 (26)** 69 (25)**
0e12 h weighted
mean Day 14
16(14) 139 (27)** 122 (27)** 143 (27)** 115 (26)** 108 (29)** 108 (28) 126 (28)** 118 (28)** 150 (27)**
12e24 h weighted
mean Day 14
101(14) 33 (26)** 34 (26)** 15 (26)** 29 (25)** 49 (28)** 14 (27) 44 (27)** 31 (27)** 11 (26)**
FVC, (mL)
Trough (Day 15) 86(31) 105 (61)* 207 (62)** 83 (60)* 114 (59)** 242 (66)** 59 (64) 141 (62)** 174 (63)** 30 (61)
0e6 h Day 1 40 (21) 329 (41)** 318 (42)** 268 (42)** 311 (41)** 221 (43)** 128 (43) 227 (41)** 223 (43)** 199 (41)**
0e6 h Day 14 6 (26) 257 (51)** 231 (51)** 208 (50)** 184 (49)** 187 (54)** 151 (52) 179 (52)** 201 (53)** 173 (51)*
0e24 h weighted
mean Day 14
83(24) 141 (44)** 157 (44)** 113 (43)** 115 (42)** 158 (47)** 73 (46) 120 (45)** 112 (45)** 29 (44)y
Albuterol use
(puffs/day)
0.264
(0.136)
0.747
(0.265)
1.048
(0.270)*
1.036
(0.270)*
1.017
(0.251)*
0.698
(0.284)
0.869
(0.266)y
1.073
(0.283)*
1.028
(0.270)*
1.152
(0.269)*
Peak FEV1 values at Day 1 and Day 14 are maximum values during 0e6 and 0e12 h, respectively; values are mean (SE); **p  0.001 vs. pl ebo; *p  0.01 vs. placebo, yp  0.05 vs. placebo.
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Table 3 Adverse events reported by 5% or more patients in any treatment group, MITT population.
GSK573719 once-daily GSK573719 twice-daily
Placebo 62.5 mg 125 mg 250 mg 500 mg 1000 mg 62.5 mg 125 mg 250 mg Tiotropium
n Z 158 n Z 35 n Z 34 n Z 36 n Z 38 n Z 32 n Z 34 n Z 37 n Z 33 n Z 35
Any adverse event 25 (16) 8 (23) 6 (18) 14 (39) 14 (37) 13 (41) 6 (18) 8 (22) 10 (30) 6 (17)
Headache 4 (3) 1 (3) 1 (3) 3 (8) 1 (3) 2 (6) 0 1 (3) 3 (9) 2 (6)
Cough 1 (<1) 1 (3) 0 1 (3) 4 (11) 2 (6) 0 0 2 (6) 0
Nasopharyngitis 2 (1) 0 0 2 (6) 0 4 (13) 2 (6) 0 0 0
Dry mouth 1 (<1) 0 0 0 1 (3) 2 (6) 0 1 (3) 3 (9) 1 (3)
Dysgeusia 0 0 0 2 (6) 0 2 (6) 1 (3) 0 2 (6) 0
Oropharyngeal pain 2 (1) 0 0 0 1 (3) 0 0 1 (3) 2 (6) 0
Dysphonia 1 (<1) 0 0 0 0 0 0 2 (5) 0 0
Hypertension 0 0 2 (6) 1 (3) 0 0 0 0 0 0
Adverse events with onset during a washout or follow-up period are not shown.
Effect of the novel LAMA GSK573719 in COPD patients 977a higher daily dose given once-daily. Evaluation of the FEV1
at 28 h was included to further characterize the broncho-
dilator efficacy of GSK573719 past the intended dosing
interval. Treatment differences between the once-daily
doses of GSK573719 at 24 h were comparable with those
at 28 h, demonstrating that bronchodilator effects were
sustained in excess of 24 h and providing further support for
a once-daily dosing interval.
Serial FEV1 curves at Day 14 showed a clear separation
for all once-daily doses of GSK573719 compared with
placebo at pre-dose and over 28 h post-dose, supporting
a once-daily dosing interval. Notably, administration of
a second dose of GSK573719 at 12 h following the morningFigure 5 Semi-log plot of individual change from baseline in
pulse rate (bpm) vs. GSK573719 Cmax (pg/mL) once-daily doses
on Day 14. qd Z once daily.dose did not result in an appreciable change in FEV1 for any
of the twice-daily doses tested. These data were supported
by findings for 0e24 h weighted mean FEV1 on Day 14 which
showed all once-daily doses of GSK573719 significantly
(p < 0.001) increased 0e24 h weighted mean FEV1 over
placebo with an effect size similar to that with twice-daily
dosing and tiotropium.
Significant improvements in FEV1 were obtained by 1 h
post-dose, which was the earliest time point tested.
Further studies will be required to fully characterize the
onset of action of GSK573719. The serial FEV1 curves
suggest the peak effect on FEV1 occurred between 3 and 6 h
post-dose. At Day 1, peak FEV1 values were generally
obtained in a larger percentage of subjects at 3 h (32e59%)
across GSK573719 once-daily doses compared with 1 h
(13%e47%) and 6 h (21e38%).
While symptom assessments were not obtained, rescue
albuterol use provided a secondary assessment of symp-
toms. Treatment with GSK573179 significantly reduced
rescue use compared with placebo at all doses tested,
except for 62.5 mg once-daily and 1000 mg once-daily, sug-
gesting symptomatic improvement with GSK573719 treat-
ment. Overall reductions in albuterol use were comparable
between once- and twice-daily dosing.
The FEV1 dose-response for GSK573719 was generally flat
with no clear dose ordering, similar to previous findings for
muscarinic receptor antagonists including tiotropium.6,14,15
This may be related to variable response based on day-to-
day variation in cholinergic tone and/or differential levels
of airway tone based on disease severity.16 However, trough
FEV1 findings from Day 15 do show a trend for improved
bronchodilator response with increasing once-daily doses,
the exception being the 250 mg once-daily dose which had
the smallest treatment difference of the once-daily doses
compared with placebo. The trough FEV1 value for 250 mg
once-daily dose appears to be anomalous based on 28 h
serial FEV1 assessments overall and pre-dose trough values
observed at Day 7 (149 mL over placebo). Further dose-
ranging work will be required to determine if the doses
evaluated are at the top of the dose-response curve,
limiting comparisons of once- and twice-daily dosing in
this study. However, the minimal bronchodilator effect
978 J.F. Donohue et al.observed after the second dose of GSK573719 may be
related to the high receptor affinity and the slow rate of
dissociation of this compound from the muscarinic
receptor, limiting additional receptor binding after the
second twice-daily dose.
GSK573719 was well tolerated at all doses, although
there was evidence for a dose-related increase in adverse
events. The incidence of AEs was similar (16e23%) for
GSK573719 doses of 62.5 mg once-daily, 125 mg once-daily,
62.5 mg twice-daily, 125 mg twice-daily, tiotropium and
placebo, with a slightly higher percentage of AEs (30e41%)
reported for the GSK573719 250 mg once-daily, 500 mg once-
daily, 1000 mg once-daily and 250 mg twice-daily primarily
due to an increased incidence of cough, dry mouth, and
dysgeusia. The incidence of common AEs associated with
anticholinergics was low (e.g., dry mouth) or not reported
(e.g., constipation, urinary retention, or eye related
events), potentially related to the exclusion of subjects
with a diagnosis of bladder neck obstruction, narrow-angle
glaucoma, or prostatic hypertrophy that based on investi-
gator judgment contra-indicated the use of an inhaled
anticholinergic. Larger scale trials will be required to
better characterize the adverse event profile of
GSK573719.
This study was limited by the use of an incomplete block
cross-over design resulting in a relatively small number of
subjects receiving each combination of treatments and
limited ability to investigate baseline imbalances and
interactions with treatment. For the primary efficacy
analysis there was some evidence of an interaction of
treatment with mean baseline, but further sensitivity
analyses gave similar results to those from the pre-defined
primary analysis and therefore it was concluded that any
interaction with baseline was not significantly impacting
study conclusions. The incomplete block cross-over design
was required to accommodate the large number of treat-
ments used to evaluate both dose-response and dosing
interval. Nonetheless, the extensive serial FEV1 profiles
obtained over 28 h provided for a rigorous assessment of
the bronchodilator activity of GSK573719, and the number
of subjects tested was adequate to identify dose-related
trends for adverse events related to tolerability.
In conclusion, GSK573719 at doses ranging from 62.5 to
1000 mg once-daily were well tolerated and provided
significant improvement in lung function for up to 28 h in
subjects with COPD, with efficacy comparable to tio-
tropium. Evaluation of dosing interval was supportive of
once-daily dosing. Doses of 62.5 and 125 mg once-daily
appear to be the optimal doses for future development.
Additional studies are warranted to further evaluate the
long-term safety and efficacy of GSK573719 alone and in
combination with vilanterol in COPD.Funding source
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